GlassScriptPhysician profile
Nancy A Spangler
NPI 1265544134
$1,058.27
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $748 · 2022: $162 · 2023: $134 · 2024: $14.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $148.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $171.93 | 2021-2024 | Belbuca |
| Nevro Corp. | $160.10 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $136.91 | 2021 | |
| Ibsa Pharma INC. | $121.44 | 2021-2023 | Tirosint, Licart |
| Boston Scientific Corporation | $96.78 | 2021 | |
| Almatica Pharma LLC | $87.97 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.47 | 2021 | |
| Emergent Biosolutions INC. | $45.00 | 2021 | |
| Neuronetics, INC. | $29.92 | 2022 | |
| Lilly USA, LLC | $25.80 | 2021 | |
| Pacira Therapeutics, INC. | $25.09 | 2021 | |
| Orthogenrx INC. | $21.12 | 2021 | |
| Baudax Bio INC. | $18.69 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $17.27 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.15 | 2023 | Quviviq |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $15.05 | 2022 | |
| Medtronic, INC. | $13.62 | 2023 | Synchromedii |
| Grt US Holding, INC. | $8.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Spangler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.